Eli Lilly (LLY)
747.01
-8.10 (-1.07%)
NYSE · Last Trade: May 20th, 6:06 PM EDT
Detailed Quote
Previous Close | 755.11 |
---|---|
Open | 756.00 |
Bid | 745.33 |
Ask | 747.00 |
Day's Range | 743.00 - 763.50 |
52 Week Range | 677.09 - 972.53 |
Volume | 3,871,081 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.000 (0.80%) |
1 Month Average Volume | 4,880,127 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Despite $6 trillion in promised investments under Trump, Goldman Sachs estimates only $30B–$135B will meaningfully impact U.S. GDP.
Via Benzinga · May 20, 2025
Marjorie Taylor Greene disclosing buying 19 different stocks in a new filing. The buys come less than two weeks after the purchase of 50 different stocks.
Via Benzinga · May 20, 2025
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
Ireland has emerged as the undisputed champion in attracting U.S. foreign direct investment, hosting an extraordinary €897 billion (over $1 trillion) in American capital. This massive investment flow has transformed the small island nation into America's premier European platform, with U.S. affiliate assets reaching approximately $2 trillion in 2021.
Via AB Newswire · May 19, 2025
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Via Benzinga · May 19, 2025
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank.
Via Investor's Business Daily · May 19, 2025
Via The Motley Fool · May 18, 2025
Via The Motley Fool · May 18, 2025
Via The Motley Fool · May 17, 2025
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts
Via MarketBeat · May 17, 2025
Eli Lilly has steadily gained market share against Novo's Wegovy which finds itself catching up.
Via Talk Markets · May 16, 2025
Via Benzinga · May 16, 2025
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Via Chartmill · May 16, 2025
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.
Via Benzinga · May 16, 2025
Wall Street fought for a fifth consecutive day of gains on Friday, with major indexes edging slightly higher by midday in New York as investors continued to digest the week's significant trade breakthroughs and recalibrate their economic expectations.
Via Benzinga · May 16, 2025
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · May 16, 2025
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Via Investor's Business Daily · May 16, 2025
Via The Motley Fool · May 16, 2025
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.
Via Benzinga · May 15, 2025
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing
Via MarketBeat · May 15, 2025